메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Study demonstrates effectiveness and economic value of…

AUCKLAND, New Zealand, Jan. 23, 2026 -- Aroa Biosurgery Limited is pleased to announce that the latest publication from its ongoing prospective study, the Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR), has been published in the Journal of Trauma and Injury. MASTRR is the largest ongoing prospective, multicenter observational study to collect patient data from the use of a bioscaffold in complex reconstruction. To date, over 450 patients have been enrolled. The study, titled "Vascularized Tissue Coverage of Trauma and Acute Care Surgery Defects with Ovine For
- 김갑성 기자
- 2026-01-23 03:13
Insilico Medicine Launches Science MMAI Gym to Transform…

[ 메디채널 김갑성 기자 ] New "AI GYM for Science" dramatically boosts the biological and chemical intelligence of any causal or frontier LLM Up to 10x performance gains on key drug discovery benchmarks compared to LLMs that miss the mark on ~75–95% of tasks Advances Insilico's vision of Pharmaceutical Superintelligence (PSI) CAMBRIDGE, Mass., Jan. 22, 2026 -- Insilico Medicine ("Insilico", HKEX: 3696), a leading global AI-driven biotech company with a clinical-stage pipeline, today announced the launch of Science MMAI Gym, a domain-specific training environment desig
- 김갑성 기자
- 2026-01-22 22:37
Mindray Unveils Three-Pillar Growth Strategy at 2026 J.P. Morgan…

SHENZHEN, China, Jan. 22, 2026 -- May Li, Board Secretary of Mindray Medical (300760.SZ), delivered a keynote speech at the 44th J.P. Morgan Healthcare Conference (JPM Conference) on January 15, 2026, outlining the company's strategic vision for the next decade centered on three core pillars: Globalization, Recurring Business Expansion, and Intelli-Digitalization. The speech also showcased significant progress in Mindray's Large Language Model (LLM) product family and innovative solutions that are redefining clinical excellence worldwide. Globalization: Deepening Localization t
- 김갑성 기자
- 2026-01-22 22:11
Mabwell Announces First-Patient Dosed in Clinical Trial of No…

SHANGHAI, Jan. 22, 2026 -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in a clinical trial in the U.S. of its independently developed novel CDH17-targeting antibody-drug conjugate (ADC) (R&D code: 7MW4911) for the treatment of advanced colorectal cancer and other advanced gastrointestinal tumors. The Phase I/II study (NCT07216560) represents the first-in-human (FIH) study of 7MW4911 in the United States. The study aims to evaluate the safety, pharmacokinetics and efficacy
- 김갑성 기자
- 2026-01-22 22:00
Jin Medical Announces the Official Commencement Date of C…

CHANGZHOU, China, Jan. 22, 2026 -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment in China, announced today that its wholly-owned subsidiary, Zhongjin Medical Equipment (Anhui) Co., Ltd., has made significant progress in the final construction of its manufacturing facility in Chuzhou, Anhui Province, China. The Company is projected to launch full capacity production by the end of April 2026. The Company completed regulatory filings wit
- 김갑성 기자
- 2026-01-22 21:57
SK bioscience, MSD, and Hilleman Laboratories Advance Za…

CEPI to provide up to USD 30 million to support development of MSD's Zaire ebolavirus vaccine Collaboration addresses manufacturing complexity and cold-chain challenges to improve yield and thermostability Partnership aims to expand affordable and sustainable vaccine access in low- and middle-income countries INCHEON, South Korea, Jan. 22, 2026 -- SK bioscience announced that it is advancing the development of a Zaire ebolavirus vaccine under a new collaboration supported by the Coalition for Epidemic Preparedness Innovations (CEPI). The announcement fol
- 김갑성 기자
- 2026-01-22 21:00
PAQ Therapeutics Announces Series B Extension, Bringing…

BURLINGTON, Mass., Jan. 22, 2026 -- PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, today announced the closing of a Series B extension, bringing the company's total Series B financing to $77 million, and the dosing of the first patient in a Phase 1 clinical trial evaluating PT0511, the company's pan-KRAS degrader. The Series B extension builds on PAQ's previously announced Series B financing, with participation from existing as well as new investors, and further strengthens the c
- 김갑성 기자
- 2026-01-22 20:00
BTL, 원더페이스 기기 관련 EMFACE® 특허권 침해 소송에서 승소

프라하, 2026년 1월 22일 -- 글로벌 의료기술 기업 BTL 그룹(BTL Group)이 원더페이스(WonderFace) 기기 제조사인 렉스터 마이크로일렉트로닉 엔지니어링 시스템즈(Lexter Microelectronic Engineering Systems S.L., 이하 '렉스터')를 상대로 한 다수의 특허권 침해 소송을 성공적으로 종결했다고 밝혔다. 이번 합의는 BTL이 자사의 EMFACE® 독점 기술을 보호하기 위해 여러 관할권에서 제기한 특허 침해 소송의 결과다. 합의에 따라 렉스터는 고주파(radiofrequency)와 전기적 근육 자극(electrical muscle stimulation)을 동시에 결합한 안면 치료 기술 및 관련 소모품의 제조, 글로벌 마케팅, 유통 및 사용을 중단하기로 했다. 의료 혁신 분야의 선도 기업인 BTL은 에너지 기반 기술의 핵심 측면을 보호하는 강력한 국제 특허 포트폴리오를 보유하고 있다. 토마시 슈바르츠(Tomas Schwarz) BTL 그룹 최고경영자(CEO)는 "이번 합의가 전 세계에 끼친 결정적인 영향은 BTL의 지식재산권을 수호하고 고객
- 김갑성 기자
- 2026-01-22 17:32
인도 텔랑가나주, '차세대 생명과학 정책 2026-30'으로 글로벌 도약 선언

[ 메디채널 김갑성 기자 ] 2030년까지 텔랑가나를 세계 5대 생명과학 클러스터로 육성 250억 달러 투자 유치 목표 규모 중시 제조에서 혁신 주도형 가치 창출 제조로 초점 전환 다보스, 스위스, 2026년 1월 22일 -- 인도 텔랑가나 주정부는 22일 스위스 다보스에서 열리고 있는 2026 세계경제포럼(WEF)에서 '차세대 생명과학 정책 2026–30(Next-Gen Life Sciences Policy 2026–30)'을 발표하며, 글로벌 헬스케어, 첨단 치료제, 지속가능한 바이오 제조업의 미래 발전을 위해 훨씬 더 중요한 역할을 수행하겠다는 의지를 분명히 했다. 규모를 중시하는 제조에서 가치 창출 중시, 혁신 주도 성장으로의 결정적 전환을 명시한 이 정책은 발견•개발•상용화 전반에 걸쳐 글로벌 종합 생명과학 허브로서 텔랑가나의 입지를 강화해줄 것이다. 특히 2030년까지 세계 5대 생명과학 클러스터 진입이라는 명확한 야망 아래, 250억 달러의 투자 유치, 50만 개의 고품질 일자리 창출, 글로벌 생명과학 가치 사슬로의 통합 강화를 목표로 한다. 탄탄한 제조 역량은 점점 더 고부가가
- 김갑성 기자
- 2026-01-22 17:29
pixelRo to Showcase AI-Powered Digital Healthcare and Air Ste…

SEOUL, South Korea, Jan. 22. 2026 -- pixelRo, a Samsung Electronics spin-off digital healthcare company, is accelerating its global expansion by participating in CES 2026 and WHX Dubai 2026 (formerly Arab Health). pixelRo develops and operates AI-based integrated self-diagnostic kiosk solutions for vision, eye health, and vital signs, all of which have obtained medical device approval. Leveraging proprietary eye-tracking technology and advanced diagnostic algorithms, the company enables fast and accurate on-site measurements of vision, macular degeneration, presbyopia accommodation, as
- 김갑성 기자
- 2026-01-22 16:59

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-31_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 31일 13시 40분